Association of MiR-149 with Nutritional Risk Assessment and Postoperative Complications of Patients with Colorectal Cancer


Colorectal cancer
Nutritional risk

How to Cite

Lin, L. ., Xu, F. ., Zhou, C. ., Quan, Z. ., & Jiang, H. (2021). Association of MiR-149 with Nutritional Risk Assessment and Postoperative Complications of Patients with Colorectal Cancer. Iranian Red Crescent Medical Journal, 23(12).


Background: MiRNAs play an important role in the development of colorectal cancer (CRC); however, there is little evidence of miRNAs in the screening of the nutritional risks of patients with CRC.

Objectives: This study aimed to explore the role of preoperative miR-149 in nutritional screening of patients with CRC, and its associations with clinicopathological characteristics and postoperative complications of patients with CRC.

Methods: The associations of serum miR-149 with clinicopathological characteristics and postoperative complications of patients were analyzed in this study. The receiver operating characteristic curves were plotted with miR-149 as the test variable, the grouping results of the patients with nutritional risks (total NRS2002 score ≥3 points), and no nutritional risks (total NRS2002 score <3 points) based on the preoperative NRS2002 score as the state variables. The consistency of miR-149 and NRS2002 in the nutritional screening of CRC was analyzed using the Kappa test.

Results: MiR-149 was low in patients with CRC. There was a statistically significant difference in the miR-149 expression among patients with different tumor diameters and TNM stages in the two groups. The preoperative total NRS2002 score of CRC patients was <3 (without nutritional risks) in 271 cases, and ≥3 (with nutritional risks) in 129 cases. The sensitivity and specificity of miR-149 in the diagnosis of nutritional risks were 76.74% and 84.50%, respectively. The Kappa value was 0.622 with miR-149=3.095 as the critical value.

Conclusion: MiR-149 can reflect the preoperative nutritional status of patients with CRC, and miR-149=3.095 can be used as the cut-off point for nutritional risk screening of patients with CRC, which is an important index for assessing the nutritional risk in the preoperative period. The expression of miR-149 has a certain association with postoperative complications.


  1. Jafarian AH, Forooshani MK, Takallou L, Roshan NM. CD10 expression in gastric carcinoma is correlated with tumor grade and survival. UnivMed. 2019;38(1):41-7. doi:
  2. Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res. 2015;2015:1-16. doi: 10.1155/2015/158038. [PubMed: 26605342].
  3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. [PubMed: 25651787].
  4. van de Velde CJ. Surgery: palliative primary tumour resection in mCRC-debate continues. Nat Rev Clin Oncol. 2015;12(3):129-30. doi: 10.1038/nrclinonc.2015.7. [PubMed: 25601445].
  5. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol. 2005;11(11):1639-43. doi: 10.3748/wjg.v11.i11.1639. [PubMed: 15786541].
  6. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M, et al. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci. 2004;49(6):970-6. doi: 10.1023/b:ddas.0000034556.48527.6e. [PubMed: 15309885].
  7. Berindan-Neagoe I, Monroig PC, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64(5):311-36. doi: 10.3322/caac.21244. [PubMed: 25104502].
  8. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203-22. doi: 10.1038/nrd.2016.246. [PubMed: 28209991].
  9. Zhang G, Liu X, Li Y, Wang Y, Liang H, Li K, et al. EphB3-targeted regulation of miR-149 in the migration and invasion of human colonic carcinoma HCT116 and SW620 cells. Cancer Sci. 2017;108(3):408-18. doi: 10.1111/cas.13161. [PubMed: 28370854].
  10. Zhou W, Wang L, Miao Y, Xing R. Novel long noncoding RNA GACAT3 promotes colorectal cancer cell proliferation, invasion, and migration through miR-149. Onco Targets Ther. 2018;11:1543-52. doi: 10.2147/OTT.S144103.
  11. Ravasco P, Monteiro-Grillo I, Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr. 2012;96(6):1346-53. doi: 10.3945/ajcn.111.018838. [PubMed: 23134880].
  12. Mohammadi A, Mansoori B, Baradaran B. The role of microRNAs in colorectal cancer. Biomed Pharmacother. 2016;84:705-13. doi: 10.1016/j.biopha.2016.09.099. [PubMed: 27701052].
  13. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1766-74. doi: 10.1158/1055-9965.EPI-10-0027. [PubMed: 20551304].
  14. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61(5):739-45. doi: 10.1136/gut.2011.239236. [PubMed: 21930727].
  15. Lv ZC, Fan YS, Chen HB, Zhao DW. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for  colorectal cancer. Tumour Biol. 2015;36(3):1619-25. doi: 10.1007/s13277-014-2760-9. [PubMed: 25528214].
  16. Luo G, Chao YL, Tang B, Li BS, Xiao YF, Xie R, et al. miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F. Oncotarget. 2015;6(35):37808-23. doi: 10.18632/oncotarget.5676. [Pubmed: 26498692].
  17. Jin L, Li Y, Liu J, Yang S, Gui Y, Mao X, et al. Tumor suppressor miR-149-5p is associated with cellular migration, proliferation  and apoptosis in renal cell carcinoma. Mol Med Rep. 2016;13(6):5386-92. doi: 10.3892/mmr.2016.5205. [PubMed: 27121091].
  18. Yang D, Du G, Xu A, Xi X, Li D. Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4. Am J Cancer Res. 2017;7(11):2209-19.  [PubMed: 29218245].
  19. Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2015;35(2):499-515. doi: 10.1159/000369715. [PubMed: 25613903].
  20. Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K, et al. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol. 2002;28(4):396-400. doi: 10.1053/ejso.2002.1257. [PubMed: 12099649].
  21. Watanabe M, Iwatsuki M, Iwagami S, Ishimoto T, Baba Y, Baba H, et al. Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg. 2012;36(7):1632-9. doi: 10.1007/s00268-012-1526-z. [PubMed: 22407085].
  22. Sorensen J, Kondrup J, Prokopowicz J, Schiesser M, Krahenbuhl L, Meier R, et al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin Nutr. 2008;27(3):340-9. doi: 10.1016/j.clnu.2008.03.012. [PubMed: 18504063].
  23. Schiesser M, Muller S, Kirchhoff P, Breitenstein S, Schafer M, Clavien PA, et al. Assessment of a novel screening score for nutritional risk in predicting complications in gastro-intestinal surgery. Clin Nutr. 2008;27(4):565-70. doi: 10.1016/j.clnu.2008.01.010. [PubMed: 18342995].
  24. Wang Y, Zheng J, Gao Z, Han X, Qiu F. Investigation on nutritional risk assessment and nutritional support status of surgical patients with colorectal cancer. J Buon. 2018;23(1):62-7. [PubMed: 29552761].